One-Sample Multiple Testing Procedure for Phase II Clinical Trials

Cited in

(37)

A review of phase 2-3 clinical trial designs
On the maximum total sample size of a group sequential test about binomial proportions.
Methodology and application of adaptive and sequential approaches in contemporary clinical trials
Exact confidence limits compatible with the result of a sequential trial
Group sequential comparison of two binomial proportions under ranked set sampling design
Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology
Monitoring the rates of composite events with censored data in phase II clinical trials
Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach
MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses
Exact confidence limits for the probability of response in two-stage designs
Improving the flexibility and efficiency of phase II designs for oncology trials
Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
SEQUENTIAL METHODS IN CLINICAL TRIALS*
Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
Optimal group sequential tests with groups of random size
Stopping for efficacy in single-arm phase II clinical trials
A class of confidence intervals for sequential phase II clinical trials with binary outcome
Determination of the optimal sample size for a clinical trial accounting for the population size
On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions
Group sequential hypothesis tests with variable group sizes: Optimal design and performance evaluation
Bayesian enhancement two-stage design with error control for phase II clinical trials
Exact confidence limits after a group sequential single arm binary trial
A Bayesian hierarchical monitoring design for phase cancer clinical trials: incorporating information on response duration into monitoring rules
Bayesian phase II clinical trial design with noncompliance
Stopping rules for phase II clinical trials: an overview
Optimal Bayesian predictive probability for delayed response in single-arm clinical trials with binary efficacy outcome
Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance
A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation
One-stage and two-stage designs for phase II clinical trials with survival endpoints
A seamless hybrid phase II/III design with Bayesian interim subgroup selection
Sample size calculation for the one-sample log-rank test
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate
Optimal group sequential hypothesis testing for exponential families of distributions: a numerical approach
Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity

This page was built for publication: One-Sample Multiple Testing Procedure for Phase II Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3938400)